carbyne

Carbyne Equity Partners' portfolio company Biomapas acquires Pinnaxis and Alira Health's CMC business, thereby strengthening its technology capabilities and expanding its US presence

Hamburg, November 16th, 2026

Biomapas, an integrated life sciences services provider and portfolio company of Carbyne Equity Partners ("Carbyne"), has agreed to acquire Pinnaxis, a global pharmacovigilance technology & AI consulting company headquartered in New Delhi India, and has completed the acquisition of the Chemistry, Manufacturing and Controls (CMC) business of Alira Health, based in Boston, USA.

Carbyne has backed Biomapas as majority shareholder since October 2024. Following the acquisition of Delta PV in 2025, the two further add-ons expand Biomapas' technology & AI capabilities, establish a US presence and add a dedicated CMC service line, advancing the group's strategy to become a leading integrated, digitally enabled global partner for lifecycle management and product development.

Pinnaxis: Digital Capabilities and an Expanded India Footprint

Pinnaxis brings more than 100 technical experts in safety system implementation, data migration, integration, validation, reporting and managed services across the principal safety platforms, including Veeva Safety Vault, Oracle Argus and ArisGlobal. Following closing, Pinnaxis will lead Biomapas' Consulting & Digital business unit, driving the use of automation and AI across the group. Its Noida – New Delhi headquarters expands Biomapas' footprint in India, while its New Jersey office and US client base complement the group's new US business.

Xavier Duburcq, CEO of Biomapas, commented on Pinnaxis: "Pinnaxis brings deep expertise in the technology behind drug safety, strengthening our ability to connect specialist services with the systems that support them. Together with our regulatory, safety and clinical teams, we will help clients manage increasingly complex requirements across the product lifecycle, combining scientific expertise with technology. This acquisition advances our ambition to build an integrated, digitally enabled partner for regulatory, safety and product development."

Alira Health CMC: A US Presence and Dedicated CMC Capabilities

The Boston-based team of more than 35 CMC experts, many with senior industry backgrounds, provides preclinical- and clinical-stage biopharma companies with the technical expertise required for successful outsourced clinical manufacturing, as well as quality assurance oversight, CMC regulatory strategy and filings, and project management. The team has supported clients across the US and Europe and forms the foundation of Biomapas' US business.

On the acquisition of Alira Health's CMC business, Xavier Duburcq added: "Establishing Biomapas North America is an important milestone for the group. The US is our clients' largest market, and the Alira Health CMC team gives us a solid base there, with strong relationships among biotech sponsors. CMC is a high-value, regulatory-driven area that sits upstream of our existing services, and the team brings specialist expertise, particularly in complex biologics. Together with our regulatory, safety and clinical teams, this lets us support clients earlier in development and across more of the product lifecycle."

Alexander Winterling, Partner at Carbyne, added: "Since our investment in 2024, Biomapas has developed into an integrated life sciences services platform with a clear international growth agenda. The acquisitions of Pinnaxis and the Alira Health CMC business demonstrate strong execution of our strategy. We look forward to continuing to support Xavier and his team in building a global partner for biopharma sponsors, both organically and through further acquisitions."

About Biomapas

Biomapas is an integrated life sciences services provider supporting pharmaceutical, biotechnology and medical device companies across the product lifecycle. The company delivers regulatory affairs, pharmacovigilance, quality assurance, medical information, clinical research and digital & consulting services, combining global standards with local expertise and technology-driven efficiency. Biomapas has offices in Luxembourg, Lithuania, Georgia, Turkey and India, a US presence through Biomapas North America, and teams in more than 30 countries.

For more information, please visit www.biomapas.com

About Carbyne Equity Partners

Carbyne Equity Partners is a private equity firm investing in growing European businesses with strong market positions and a commitment to innovation. Its focus spans healthcare, nutrition and agricultural inputs, sectors where the firm leverages its extensive network of entrepreneurial investors. Working closely with management teams, Carbyne supports businesses in accelerating growth and strengthening long-term market leadership.

For more information, please visit www.carbynepartners.de